123 related articles for article (PubMed ID: 35964660)
1. Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer.
Bailly C
Eur J Pharmacol; 2022 Sep; 931():175191. PubMed ID: 35964660
[TBL] [Abstract][Full Text] [Related]
2. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
3. The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer.
Ji J; Xu MX; Qian TY; Zhu SZ; Jiang F; Liu ZX; Xu WS; Zhou J; Xiao MB
Mol Biol Rep; 2020 Aug; 47(8):6091-6103. PubMed ID: 32761301
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Kikuya M; Furuichi K; Hirao T; Endo S; Toyooka N; Ito K; Aoki S
J Pharmacol Sci; 2021 Sep; 147(1):1-8. PubMed ID: 34294359
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
6. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
7. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
8. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
9. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
[TBL] [Abstract][Full Text] [Related]
11. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
[TBL] [Abstract][Full Text] [Related]
12. (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors.
Kucerova-Chlupacova M; Halakova D; Majekova M; Treml J; Stefek M; Soltesova Prnova M
Chem Biol Interact; 2020 Dec; 332():109286. PubMed ID: 33038328
[TBL] [Abstract][Full Text] [Related]
13. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients.
Sato N; Kashima K; Uehara Y; Ohtani K; Shimizu H; Mori M
Diabetes Care; 1997 Jun; 20(6):995-8. PubMed ID: 9167113
[TBL] [Abstract][Full Text] [Related]
14. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
[TBL] [Abstract][Full Text] [Related]
15. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
[TBL] [Abstract][Full Text] [Related]
16. Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
Banala VT; Urandur S; Sharma S; Sharma M; Shukla RP; Marwaha D; Gautam S; Dwivedi M; Mishra PR
Biomater Sci; 2019 Jun; 7(7):2889-2906. PubMed ID: 31086900
[TBL] [Abstract][Full Text] [Related]
17. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
18. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
[TBL] [Abstract][Full Text] [Related]
19. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
[TBL] [Abstract][Full Text] [Related]
20. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
